<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=3>SECURITIES AND
EXCHANGE COMMISSION<BR>WASHINGTON, D. C. 20549 </FONT></H1>


<!-- MARKER FORMAT-SHEET="Head Major Center Bold" FSL="Default" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=3>FORM 8-K<BR>CURRENT REPORT </FONT></H1>

<!-- MARKER FORMAT-SHEET="Page Rule Single" FSL="Default" -->
     <HR ALIGN=LEFT WIDTH=100% SIZE=1 NOSHADE>

<!-- MARKER FORMAT-SHEET="Head Minor Center" FSL="Default" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>PURSUANT TO SECTION 13
OR 15(d) OF<BR> THE SECURITIES EXCHANGE ACT OF 1934 </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Minor Center" FSL="Default" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Date of Report (Date of earliest event reported) <BR><B>May 19, 2005 </B></FONT></P>


<!-- MARKER FORMAT-SHEET="Head Minor Center Bold" FSL="Default" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=3><B>MedImmune, Inc.</B><BR>(Exact
name of registrant as specified in its charter)</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" WIDTH="600">
<TR VALIGN=Bottom>
     <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
     <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
     <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TD WIDTH="33%" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delaware</FONT></TD>
     <TD WIDTH="33%" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0-19131</FONT></TD>
     <TD WIDTH="34%" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>52-1555759</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(State or other jurisdiction of</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(Commission File No.)</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(I.R.S. Employer Identification No.)</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;incorporation or organization)</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD></TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Head Minor Center" FSL="Default" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>One MedImmune Way,
 Gaithersburg, MD 20878</B><BR>(Address of principal executive offices) (Zip Code) </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Large Indent" FSL="Default" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Registrant&#146;s
telephone number, including area code (301) 398-0000 </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (<I>see
</I>General Instruction A.2. below): </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;|_|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;|_| Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;|_|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;|_|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) </FONT></P>

<!-- MARKER PAGE="sheet: 1; page: 1" -->
<HR SIZE=5 COLOR=GRAY NOSHADE>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<A NAME=A001></A>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=3>Section 1 &#150;
Registrant&#146;s Business and Operations </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<A NAME=A002></A>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=3>Item 1.01 &#150; Entry
into a Material Definitive Agreement </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
May 19, 2005, at the MedImmune, Inc. (the &#147;Company&#148;) Annual Meeting of
Stockholders, the Company&#146;s stockholders approved the amendment of the Company&#146;s
2004 Stock Incentive Plan (the &#147;2004 Plan&#148;) thereby transferring to the 2004
Plan 2,000,000 shares which were previously allocated to the Company&#146;s 1999 Stock
Option Plan (the &#147;1999 Plan&#148;). In addition, the Company&#146;s stockholders
approved the further increase of the number of shares subject to the 2004 Plan by
6,000,000 shares, which, taken together with the transfer from the 1999 Plan, increased
the maximum number of shares of common stock authorized for issuance under the 2004 Plan
by 8,000,000, from 13,000,000 to 21,000,000. Also, the number of shares that may be
subject to awards of restricted stock, stock units and stock awards under the 2004 Plan
was increased from 3,000,000 shares to 6,000,000 shares. &nbsp; </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
summary description of the terms of the 2004 Plan, and the amendments approved by the
stockholders, are set forth in the Company&#146;s definitive proxy statement on Schedule
14A (the &#147;Proxy Statement&#148;) filed with the Securities and Exchange Commission on
April 15, 2005. The section of the Proxy Statement entitled &#147;Proposal 2 &#150;
Approval of Amendment to the 2004 Stock Incentive Plan&#148; is incorporated herein by
reference. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<A NAME=A003></A>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=3>Section 5 &#151;
Corporate Governance and Management </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>Item 5.02 Departure of Directors
or Principal Officers; Election of Directors; Appointment of Principal Officers.</B> </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
April 6, 2005, the Company filed a Current Report on Form 8-K (the &#147;April 6
8-K&#148;) stating that, effective April 1, 2005, the Board of Directors of the Company
(the &#147;Board&#148;) had elected George M. Milne, Jr., Ph.D. as a Director to fill the
vacancy created by the resignation of Mr. Melvin D. Booth. At that time, the Board had not
determined the committees of the Board on which Dr. Milne would serve. On May 19, 2005,
following election of Dr. Milne to the Board by the Company&#146;s stockholders at its
annual stockholder meeting, the Board appointed Dr. Milne to serve on its Compensation and
Stock Committee and its Corporate Governance and Nominating Committee. Item 5.02 of the
April 6 8-K is hereby amended to reflect such appointments. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<A NAME=A004></A>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=3>Item 5.03 Amendments to
Articles of Incorporation or Bylaws; Change in Fiscal Year </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para (List) Hang " FSL="Default" -->
     <TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
          <TR VALIGN=TOP>
          <TD ALIGN=LEFT WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>(a)</B> </FONT></TD>
          <TD WIDTH=97%><P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
          Effective May 19, 2005, the Board amended Article IV, Section 1 of the
          Company&#146;s By-laws. Prior to this amendment, such provision read as follows: </FONT></P></TD>
          </TR>
          </TABLE>
          <BR>

<!-- MARKER FORMAT-SHEET="Para Flush Level 3" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=15%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp; </FONT></TD>
<TD WIDTH=85%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Executive
Officers</U>. The executive officers of the Corporation shall be a Chief Executive
Officer, a President, a Chief Financial Officer, a Secretary and a Treasurer and may
include a Chairman, a Vice Chairman and such other executive officers as the Board may
deem necessary. Any two or more offices may be held by the same person. </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following
this amendment, such provision now reads as follows: </FONT></P>



<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=15%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp; </FONT></TD>
<TD WIDTH=85%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Officers</U>. The executive officers of the Corporation shall be its Chief Executive Officer
          and such other executive officers as the Board (or a duly authorized committee
          of the Board) may deem necessary from time to time. In addition, the Corporation
          shall have a Secretary, a Treasurer and such other officers as the Board (or a
          duly authorized committee of the Board) may deem necessary from time to time
          consistent with the responsibilities set forth in this Article IV for certain
          specified officers or as otherwise determined appropriate by the Board. Any two
          or more offices may be held by the same person.  </FONT></TD>
</TR>
</TABLE>

<BR>


<!-- MARKER PAGE="sheet: 1; page: 1" -->
<HR SIZE=5 COLOR=GRAY NOSHADE>



<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SIGNATURE </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold" FSL="Default" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MEDIMMUNE, INC. </FONT></H1>

<!-- MARKER FORMAT-SHEET="Signature (Single)" FSL="Project" -->
<TABLE WIDTH=100% CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=40%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=10%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=50%><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B></B><BR><BR>
<BR>By: /s/: William C. Bertrand, Jr.<BR>&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;<BR>
William C. Bertrand, Jr.<BR>Vice President,&nbsp;Secretary and General Counsel</FONT></TD>
</TR>
</TABLE>
<BR><BR>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Date:  May 24, 2005</FONT></P>



</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "annualmeeting.htm", "description": "ANNUAL MEETING", "secsgml_size_bytes": 13276}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19131", "film-number": "05854012"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13
OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported)
May 19, 2005
MedImmune, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
0-19131
52-1555759
(State or other jurisdiction of
(Commission File No.)
(I.R.S. Employer Identification No.)
incorporation or organization)
One MedImmune Way,
 Gaithersburg, MD 20878
(Address of principal executive offices) (Zip Code)
Registrant's
telephone number, including area code (301) 398-0000
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
|_|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|_| Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|_|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|_|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Section 1 –
Registrant's Business and Operations
Item 1.01 – Entry
into a Material Definitive Agreement
On
May 19, 2005, at the MedImmune, Inc. (the "Company") Annual Meeting of
Stockholders, the Company's stockholders approved the amendment of the Company's
2004 Stock Incentive Plan (the "2004 Plan") thereby transferring to the 2004
Plan 2,000,000 shares which were previously allocated to the Company's 1999 Stock
Option Plan (the "1999 Plan"). In addition, the Company's stockholders
approved the further increase of the number of shares subject to the 2004 Plan by
6,000,000 shares, which, taken together with the transfer from the 1999 Plan, increased
the maximum number of shares of common stock authorized for issuance under the 2004 Plan
by 8,000,000, from 13,000,000 to 21,000,000. Also, the number of shares that may be
subject to awards of restricted stock, stock units and stock awards under the 2004 Plan
was increased from 3,000,000 shares to 6,000,000 shares.
A
summary description of the terms of the 2004 Plan, and the amendments approved by the
stockholders, are set forth in the Company's definitive proxy statement on Schedule
14A (the "Proxy Statement") filed with the Securities and Exchange Commission on
April 15, 2005. The section of the Proxy Statement entitled "Proposal 2 –
Approval of Amendment to the 2004 Stock Incentive Plan" is incorporated herein by
reference.
Section 5 —
Corporate Governance and Management
Item 5.02 Departure of Directors
or Principal Officers; Election of Directors; Appointment of Principal Officers.
On
April 6, 2005, the Company filed a Current Report on Form 8-K (the "April 6
8-K") stating that, effective April 1, 2005, the Board of Directors of the Company
(the "Board") had elected George M. Milne, Jr., Ph.D. as a Director to fill the
vacancy created by the resignation of Mr. Melvin D. Booth. At that time, the Board had not
determined the committees of the Board on which Dr. Milne would serve. On May 19, 2005,
following election of Dr. Milne to the Board by the Company's stockholders at its
annual stockholder meeting, the Board appointed Dr. Milne to serve on its Compensation and
Stock Committee and its Corporate Governance and Nominating Committee. Item 5.02 of the
April 6 8-K is hereby amended to reflect such appointments.
Item 5.03 Amendments to
Articles of Incorporation or Bylaws; Change in Fiscal Year
(a)
Effective May 19, 2005, the Board amended Article IV, Section 1 of the
          Company's By-laws. Prior to this amendment, such provision read as follows:
Executive
Officers
. The executive officers of the Corporation shall be a Chief Executive
Officer, a President, a Chief Financial Officer, a Secretary and a Treasurer and may
include a Chairman, a Vice Chairman and such other executive officers as the Board may
deem necessary. Any two or more offices may be held by the same person.
Following
this amendment, such provision now reads as follows:
Officers
. The executive officers of the Corporation shall be its Chief Executive Officer
          and such other executive officers as the Board (or a duly authorized committee
          of the Board) may deem necessary from time to time. In addition, the Corporation
          shall have a Secretary, a Treasurer and such other officers as the Board (or a
          duly authorized committee of the Board) may deem necessary from time to time
          consistent with the responsibilities set forth in this Article IV for certain
          specified officers or as otherwise determined appropriate by the Board. Any two
          or more offices may be held by the same person.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MEDIMMUNE, INC.
By: /s/: William C. Bertrand, Jr.
——————————————
William C. Bertrand, Jr.
Vice President, Secretary and General Counsel
Date:  May 24, 2005